EA201792662A1 - Специфические антитела к т-клеточному рецептору - Google Patents

Специфические антитела к т-клеточному рецептору

Info

Publication number
EA201792662A1
EA201792662A1 EA201792662A EA201792662A EA201792662A1 EA 201792662 A1 EA201792662 A1 EA 201792662A1 EA 201792662 A EA201792662 A EA 201792662A EA 201792662 A EA201792662 A EA 201792662A EA 201792662 A1 EA201792662 A1 EA 201792662A1
Authority
EA
Eurasian Patent Office
Prior art keywords
chains
cell receptor
specific antibodies
tcr
binds
Prior art date
Application number
EA201792662A
Other languages
English (en)
Inventor
Долорес Шендель
Славолюб Милошевич
Таня Херрманн
Михаэла Кюглер
Original Assignee
Медиджин Иммьюнотерапиз Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Медиджин Иммьюнотерапиз Гмбх filed Critical Медиджин Иммьюнотерапиз Гмбх
Publication of EA201792662A1 publication Critical patent/EA201792662A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies

Abstract

Изобретение относится к антителу или его связывающему фрагменту, который связывается с фракцией вариабельных альфа-цепей T-клеточного рецептора (TCR Vα), включающей по меньшей мере две различные TCR Vα цепи, но меньше всех TCR Vα цепей, или который связывается с фракцией вариабельных бета-цепей T-клеточного рецептора (TCR Vβ), включающей по меньшей мере две различные TCR Vβ цепи, но меньше всех TCR Vβ цепей.
EA201792662A 2015-06-01 2016-06-01 Специфические антитела к т-клеточному рецептору EA201792662A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15170154 2015-06-01
PCT/EP2016/062370 WO2016193301A1 (en) 2015-06-01 2016-06-01 T-cell receptor specific antibodies

Publications (1)

Publication Number Publication Date
EA201792662A1 true EA201792662A1 (ru) 2018-04-30

Family

ID=53298194

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201792662A EA201792662A1 (ru) 2015-06-01 2016-06-01 Специфические антитела к т-клеточному рецептору

Country Status (14)

Country Link
US (1) US20180256716A1 (ru)
EP (1) EP3303389A1 (ru)
JP (1) JP2018517712A (ru)
KR (1) KR20180020202A (ru)
CN (1) CN108026171A (ru)
AU (1) AU2016273215B2 (ru)
BR (1) BR112017025332A2 (ru)
CA (1) CA2987877A1 (ru)
EA (1) EA201792662A1 (ru)
HK (1) HK1253695A1 (ru)
MX (1) MX2017015619A (ru)
NZ (1) NZ737851A (ru)
PH (1) PH12017502190A1 (ru)
WO (1) WO2016193301A1 (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016193300A1 (en) 2015-06-01 2016-12-08 Medigene Immunotherapies Gmbh Method for generating antibodies against t cell receptor
NZ737400A (en) 2015-06-01 2019-09-27 Medigene Immunotherapies Gmbh T cell receptor library
CA3009542C (en) 2015-12-23 2023-08-29 Medigene Immunotherapies Gmbh Novel generation of antigen-specific tcrs
CN107827959B (zh) * 2017-11-09 2018-10-30 杭州续缓生物科技有限公司 识别乙肝病毒(hbv)表面抗原s183-91表位的tcr及其用途
AU2019297451A1 (en) * 2018-07-03 2021-01-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
AU2020204686A1 (en) * 2019-01-04 2021-07-22 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
JP2022523502A (ja) * 2019-01-29 2022-04-25 シャンハイ ジャオ トン ユニバーシティ キメラ抗原受容体およびその使用
SG11202109056TA (en) * 2019-02-21 2021-09-29 Marengo Therapeutics Inc Multifunctional molecules that bind to calreticulin and uses thereof
AU2020226904A1 (en) * 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
SG11202109033XA (en) * 2019-02-21 2021-09-29 Marengo Therapeutics Inc Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
CN112409474B (zh) * 2019-08-23 2023-02-28 香雪生命科学技术（广东）有限公司 一种识别ssx2抗原的高亲和力tcr
AU2020384369A1 (en) * 2019-11-14 2022-05-26 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
AU2020416273A1 (en) * 2020-01-03 2022-07-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
US20230108300A1 (en) * 2020-01-29 2023-04-06 The Trustees Of The University Of Pennsylvania Compositions and methods of t cell receptor vb family member targeting for the treatment of t cell associated disease
CN112147326B (zh) * 2020-09-04 2022-04-08 北京大学 一种肿瘤免疫细胞亚群分型精准检测试剂盒

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169938A (en) * 1987-04-25 1992-12-08 Kyowa Hakko Kogyo Co., Ltd. Anti-T cell receptor γ-chain monoclonal antibody
US5766947A (en) * 1988-12-14 1998-06-16 Astra Ab Monoclonal antibodies reactive with an epitope of a Vβ3.1 variable region of a T cell receptor
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
WO1991007508A1 (en) * 1989-11-15 1991-05-30 National Jewish Center For Immunology And Respiratory Medicine Method for measuring t-cell surface antigens in humans
US5480895A (en) * 1991-09-27 1996-01-02 New York Society For The Relief Of The Ruptured And Crippled, Maintaining The Hospital For Special Surgery Method of producing antibodies to a restricted population of T lymphocytes, antibodies produced therefrom and methods of use thereof
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
JP2702285B2 (ja) 1992-08-21 1998-01-21 バイオジェン，インコーポレイテッド Ｔａｔ由来の輸送ポリペプチド
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6566329B1 (en) 1999-06-28 2003-05-20 Novo Nordisk A/S Freeze-dried preparation of human growth hormone
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
WO2003025020A1 (fr) 2001-09-13 2003-03-27 Institute For Antibodies Co., Ltd. Procede pour creer une banque d'anticorps de chameaux
GB0911566D0 (en) * 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors
SG10201407519TA (en) * 2009-11-19 2015-01-29 Univ Singapore Method For Producing T Cell Receptor-Like Monoclonal Antibodies And Uses Thereof
CN102295702B (zh) * 2011-08-26 2014-01-29 中国科学院微生物研究所 一种针对t细胞受体可变区特异性单抗的制备方法
UY34317A (es) * 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß

Also Published As

Publication number Publication date
KR20180020202A (ko) 2018-02-27
NZ737851A (en) 2019-08-30
MX2017015619A (es) 2018-08-15
AU2016273215B2 (en) 2019-04-11
JP2018517712A (ja) 2018-07-05
AU2016273215A1 (en) 2017-12-21
CA2987877A1 (en) 2016-12-08
HK1253695A1 (zh) 2019-06-28
EP3303389A1 (en) 2018-04-11
PH12017502190A1 (en) 2018-06-11
CN108026171A (zh) 2018-05-11
US20180256716A1 (en) 2018-09-13
BR112017025332A2 (pt) 2018-07-31
WO2016193301A1 (en) 2016-12-08

Similar Documents

Publication Publication Date Title
EA201792662A1 (ru) Специфические антитела к т-клеточному рецептору
CY1123409T1 (el) Αντισωματα κατα toy icos (επαγωγιμος συνδιεγερτης τ-κυτταρων)
CO2018011364A2 (es) Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos
CY1125008T1 (el) Χιμαιρικοι υποδοχεις αντιγονων που στοχευουν συζευγμενους με πρωτεϊνη g yποδοχεις και χρησεις αυτων
CO2018010538A2 (es) Anticuerpos específicos del receptor de poliovirus humano (rvp)
DK3389682T3 (da) Gruppe b-adenovirus, der koder for et anti-tcr-kompleks-antistof eller -fragment
PH12018501042A1 (en) Antibodies and antibody fragments for site-specific conjugation
IL263083A (en) single chain variable segment cd3 binding proteins
MX2023006482A (es) Anticuerpos biespecificos especificos para un receptor de tnf coestimulador.
IL250321A0 (en) Monoclonal antibody against ctla4 or its conjugated antigen residue, pharmaceutical composition and uses
BR112018001955A2 (pt) anticorpos monoclonais contra bcma
MX2018008308A (es) Proteinas de fusion de union a 41bb multivalentes y multiespecificas.
DK3337824T3 (da) Anti-bcma-antistoffer, bispecifikke antigen-bindende molekyler, som binder bcma og cd3, og anvendelse deraf
MX2019008146A (es) Virus alterado.
CR20170383A (es) Anticuerpos anti-cd3, anticuerpos anti-cd-123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
DK3795177T3 (da) Claudin-18.2-specifikke immunoreceptorer og t-celleepitoper
EA201992536A1 (ru) Tcr и пептиды
BR112018075644A2 (pt) anticorpos anti-cd98 e conjugados de anticorpo e fármaco
CL2018000946A1 (es) Proteínas de unión a antigeno que activan el receptor de leptina
BR112016025056A2 (pt) uso de pelo menos um polipeptídeo, anticorpo biespecífico, anticorpo biespecífico isolado, anticorpo her3/her2 biespecífico, célula hospedeira, método de produção do anticorpo biespecífico her3/her2, imunoconjugado e formulação farmacêutica
CO2020006453A2 (es) Anticuerpos anti-cxcr5 y composiciones y usos de los mismos
EA201890078A1 (ru) Антитело
BR112019008345A2 (pt) anticorpos monoclonais ligados à isoforma transmembrana cd160
BR112017012515A2 (pt) membros vinculantes para c-maf humano
HK1256286A1 (zh) 結合人大麻素1(cb1)受體的抗體